Mechanisms of resistance to topoisomerase I-targeting drugsRASHEED, Zeshaan A; RUBIN, Eric H.Oncogene (Basingstoke). 2003, Vol 22, Num 47, pp 7296-7304, issn 0950-9232, 9 p.Article

Topotecan-induced bronchiolitisEDGERTON, Colin C; GILMAN, Matthew; ROTH, Bernard J et al.Southern medical journal (Birmingham). 2004, Vol 97, Num 7, pp 699-701, issn 0038-4348, 3 p.Article

A phase I study of Topotecan, as a radiosensitizer, for thoracic malignanciesFOROUZANNIA, Afshin; SCHILLER, Joan; BERLIN, Jordan et al.Lung cancer. 2004, Vol 44, Num 1, pp 111-119, issn 0169-5002, 9 p.Article

Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecanFISCHER, L; THIEL, E; KLASEN, H. A et al.Neurology. 2004, Vol 62, Num 10, pp 1885-1887, issn 0028-3878, 3 p.Article

In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant gliomaCIUSANI, Emilio; CROCI, Danilo; GELATI, Maurizio et al.Journal of neuro-oncology. 2005, Vol 71, Num 1, pp 19-25, issn 0167-594X, 7 p.Article

A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradientYUEHUI YANG; YANLING MA; SHAONING WANG et al.European journal of pharmaceutics and biopharmaceutics. 2012, Vol 80, Num 2, pp 332-339, issn 0939-6411, 8 p.Article

Treatment options for endometrial cancer: experience with topotecanHOLLOWAY, Robert W.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp S28-S33, issn 0090-8258, 2Conference Paper

Workshop: options for therapy in ovarian cancerHERZOG, Thomas J; HOLLOWAY, Robert W; STUART, Gavin C. E et al.Gynecologic oncology (Print). 2003, Vol 90, Num 3, pp S45-S50, issn 0090-8258, 2Conference Paper

Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantroneYANG, Chih-Hsin; CHEN, Yao-Chang; KUO, Min-Liang et al.Anticancer research. 2003, Vol 23, Num 3B, pp 2519-2523, issn 0250-7005, 5 p.Article

A Semi-physiological-Based Pharmacokinetic/Pharmacodynamic Model to Describe the Effects of Topotecan on B-Lymphocyte Lineage CellsVELEZ DE MENDIZABAL, Nieves; MARTINEZ-FORERO, Iván; GARRIDO, María J et al.Pharmaceutical research. 2010, Vol 27, Num 3, pp 431-441, issn 0724-8741, 11 p.Article

Development of a highly stable and targetable nanoliposomal formulation of topotecanDRUMMOND, Daryl C; NOBLE, Charles O; BENZ, Christopher C et al.Journal of controlled release. 2010, Vol 141, Num 1, pp 13-21, issn 0168-3659, 9 p.Article

Topotecan-carboplatin-etoposide combination as 1 st line treatment in patients with small cell lung cancerZAROGOULIDIS, K; MYLONAKI, E; KAKAVELAS, P et al.Lung cancer. 2009, Vol 66, Num 2, pp 226-230, issn 0169-5002, 5 p.Article

Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenograftsBALSARI, A; TORTORETO, M; BESUSSO, D et al.European journal of cancer (1990). 2004, Vol 40, Num 8, pp 1275-1281, issn 0959-8049, 7 p.Article

Concurrent chemoradiotherapy and adjuvant chemotherapy with topotecan for patients with glioblastoma multiformeKLAUTKE, G; SCHÜTZE, M; BOMBOR, I et al.Journal of neuro-oncology. 2006, Vol 77, Num 2, pp 199-205, issn 0167-594X, 7 p.Article

Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancerHUBER, R. M; PECK, M; GOSSE, H et al.The European respiratory journal. 2006, Vol 27, Num 6, pp 1183-1189, issn 0903-1936, 7 p.Article

Phase-i study of a new schedule based on increasing days of topotecan administration associated with dose individualisationDELORD, Jean-Pierre; LEGER, Frédéric; CANAL, Pierre et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 189-194, issn 0344-5704, 6 p.Article

A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytomaPIPAS, J. Marc; MEYER, Louise P; RHODES, C. Harker et al.Journal of neuro-oncology. 2005, Vol 71, Num 3, pp 301-305, issn 0167-594X, 5 p.Article

Nigericin-mediated liposome loading of topotecan: Is nigericin a potential drug release regulator?JINGXIA CUI; CHUNLEI LI; CAIXIA WANG et al.International journal of pharmaceutics (Print). 2010, Vol 399, Num 1-2, pp 31-36, issn 0378-5173, 6 p.Article

Therapy of small cell lung cancer with emphasis on oral topotecanPIRKER, Robert; BERZINEC, Peter; STANCULEANU, Dana et al.Lung cancer. 2010, Vol 70, Num 1, pp 7-13, issn 0169-5002, 7 p.Article

A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancerSHIBAYAMA, Takuo; HOTTA, Katsuyuki; KUYAMA, Shoichi et al.Lung cancer. 2006, Vol 53, Num 2, pp 189-195, issn 0169-5002, 7 p.Article

Copper-topotecan complexation mediates drug accumulation into liposomesTAGGAR, Amandeep S; ALNAJIM, Jehan; ANANTHA, Malathi et al.Journal of controlled release. 2006, Vol 114, Num 1, pp 78-88, issn 0168-3659, 11 p.Article

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors : A children's oncology group studyHAWKINS, Douglas S; BRADFIELD, Scott; WHITLOCK, James A et al.Pediatric blood & cancer. 2006, Vol 47, Num 6, pp 790-794, issn 1545-5009, 5 p.Article

Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasmaVALI, A. M; SHAFAGHI, B; DADASHZADEH, S et al.Journal of chromatography. B. 2005, Vol 818, Num 2, pp 205-212, issn 1570-0232, 8 p.Article

Topotecan as first-line therapy for small cell lung cancerGRECO, F. Anthony.Lung cancer. 2003, Vol 41, pp S9-S16, issn 0169-5002, SUP4Article

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group studyMILLER, David Scott; BLESSING, John A; LENTZ, Samuel S et al.Gynecologic oncology (Print). 2002, Vol 87, Num 3, pp 247-251, issn 0090-8258, 5 p.Article